P. Harter Et Al. , "DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.37, Illinois, United States Of America, 2019
Harter, P. Et Al. 2019. DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Harter, P., Bidzinski, M., Colombo, N., Floquet, A., Rubio Perez, M. J., Kim, J., ... Lheureux, S.(2019). DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Harter, Philipp Et Al. "DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2019
Harter, Philipp Et Al. "DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2019
Harter, P. Et Al. (2019) . "DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Philipp Harter Et Al. }, title={DUO-O: A randomized phase Ill trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2019}}